ClinicalTrials.gg
RecruitingNCT06162897CM2Updated Nov 19, 2026

Case Management Dyad

An interventional study of Dyadic Case Management in HIV, Pre-exposure Prophylaxis and Case Management, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Chicago · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2022, registered Nov 2023).
  • Started Sep 2022; still recruiting 4 years 2 months later.
Updated Nov 19, 2026Primary completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The overall goal of this study is to test whether dyadic and focused case management coupled with contingency management will (1) improve financial wellbeing, (2) improve access to food, (3) increase linkage and retention rates for individuals living with HIV or those taking PrEP (PrEP persistence), and (4) increase the proportion of individuals living with HIV who are virally suppressed (viral suppression) when compared to routine Ryan White Non-Medical Case Management.

Read the detailed description

The purpose of this research is to test the impact of dyadic, focused case management coupled with contingency management on financial well-being, access to food, linkage to and retention in care outcomes for individuals living with or vulnerable to HIV.

The study team will be testing the hypotheses that dyadic case management that is focused on financial wellness coupled with contingency management, will have better outcomes for folks living with or vulnerable to HIV. Analyses will be used to assess the efficacy of the intervention as an emerging practice.

02

Conditions studied

  • HIV
  • Pre-exposure Prophylaxis
  • Case Management
  • Contingency Management

Keywords

  • linkage to care
  • viral suppression
  • case management
  • retention in care
  • financial wellbeing
  • food security
03

In context

Lead sponsor

University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.

Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Gap in or PrEP care access in the past 24 months, defined as a gap greater than 6 months or detectable viral load at least one time in the past 24 months

Self-reported financial or food insecurity

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • No intervention
    Treatment as usual

    Participants will be offered the current standard of care, Ryan White Non-Medical Case Management. Case management services are need focused and contact is client initiated.

  • Experimental
    Dyadic Case Management

    Participants will receive dyadic case management, specifically they will have two case managers assigned to their case. Case management services will be goal focused and will utilize components from Appreciative Inquiry to orient work to future planning, goals, and financial stability.

    Behavioral: Dyadic Case Management

Interventions

  • BehavioralDyadic Case Management

    Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals. Clients will receive conditional cash transfers for medical visit attendance and negative HIV/syphilis tests or undetectable viral loads.

06

What researchers measure

Primary outcomes

  1. Financial wellbeing

    Proportion of subjects who report improved financial wellbeing (e.g. consistent income, ability to pay bills).

    Time frame: 18 months

  2. Food Security

    Proportion of individuals who report improved access to food (e.g. fewer gaps in access to food, reduced concern about access to food).

    Time frame: 18 months

Secondary outcomes

  1. PrEP Persistence

    Proportion of individuals who have engaged in PrEP care regularly (beyond 6 months).

    Time frame: 18 months

  2. Viral Suppression

    Proportion of individuals who have a viral load below 200 copies/mL

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Evans WN, Sullivan JX, Wallskog M. The impact of homelessness prevention programs on homelessness. Science. 2016 Aug 12;353(6300):694-9. doi: 10.1126/science.aag0833. Epub 2016 Aug 11. PubMed 27516600 ↗
  • Bailey ZD, Krieger N, Agenor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017 Apr 8;389(10077):1453-1463. doi: 10.1016/S0140-6736(17)30569-X. PubMed 28402827 ↗
  • Singer AW, Weiser SD, McCoy SI. Does Food Insecurity Undermine Adherence to Antiretroviral Therapy? A Systematic Review. AIDS Behav. 2015 Aug;19(8):1510-26. doi: 10.1007/s10461-014-0873-1. PubMed 25096896 ↗
  • Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, Hucks-Ortiz C, Kuo I, Lucas J, Magnus M, Mayer KH, Nelson LE, Hendrix CW, Piwowar-Manning E, Shoptaw S, Watkins P, Watson CC, Wilton L. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc. 2019 Feb;22(2):e25223. doi: 10.1002/jia2.25223. PubMed 30768776 ↗
  • Lopez JD, Shacham E, Brown T. The Impact of Clinic Policy Attendance and the Ryan White HIV/AIDS Medical Case Management Program on HIV Clinical Outcomes: A Retrospective Longitudinal Study. AIDS Behav. 2020 Apr;24(4):1161-1169. doi: 10.1007/s10461-019-02738-8. PubMed 31768689 ↗
  • Bouris A, Jaffe K, Eavou R, Liao C, Kuhns L, Voisin D, Schneider JA. Project nGage: Results of a Randomized Controlled Trial of a Dyadic Network Support Intervention to Retain Young Black Men Who Have Sex With Men in HIV Care. AIDS Behav. 2017 Dec;21(12):3618-3629. doi: 10.1007/s10461-017-1954-8. PubMed 29079949 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 8, 2023
StartActual
Sep 9, 2022
Primary completionEst.
Nov 30, 2026was Sep 2026
CompletionEst.
Jun 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Nov 30, 2026
Nov 19, 2026
Enrollment
180→220
Oct 2, 2026
Show all 2 updates
  1. Nov 19, 2026
    Primary completion Sep 30, 2026→Nov 30, 2026
    + 2 other changes: verification date and contact details
  2. Oct 2, 2026
    Enrollment 180→220
    + 5 other changes: verification date, description, conditions, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06162897
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Sep 9, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Rebecca Eavou
Contact
reavou@bsd.uchicago.edu
773-834-2336
John Schneider, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion